Zoledronic acid hydrate for cell activation

Zoledronic acid is a third-generation bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption. It displays high affinity for hydroxyapatite (Ki = 3.47 μM) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis. At micromolar concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis. Zoledronic acid has been used in the treatment of osteoporosis, Paget’s disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.

N/A

165800-06-6

290.1

Biochemicals

(1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; NDC-zoledronate; zoledronate; Zometa; Reclast ; CGP 42446;  CGP42446A;  ZOL 446

C₅H₁₂N₂O₈P₂

Crystaline solid

N/A

No

Yes

≥98%

PBS (~ 1.6 mg/ml)

-20°C

gel pack

36 months

Protect from air and moisture

cell

For cells, cell lines and tissues in culture till half confluency.